Country: Կանադա
language: անգլերեն
source: Health Canada
ISOSORBIDE-5-MONONITRATE
SIVEM PHARMACEUTICALS ULC
C01DA14
ISOSORBIDE MONONITRATE
60MG
TABLET (EXTENDED-RELEASE)
ISOSORBIDE-5-MONONITRATE 60MG
ORAL
30/100
Ethical
NITRATES AND NITRITES
Active ingredient group (AIG) number: 0120456002; AHFS:
CANCELLED POST MARKET
2017-06-27
PRODUCT MONOGRAPH Pr ISMN Isosorbide-5-mononitrate extended release tablets, BP 60 mg Antianginal Agent SIVEM PHARMACEUTICALS ULC 4705 Dobrin Street Saint-Laurent, Quebec H4R 2P7 www.sivem.ca Date of Preparation: September 21, 2015 Submission Control No.: 187095 Sivem TM is a trademark of Sivem Pharmaceuticals ULC PRODUCT MONOGRAPH NAME OF DRUG ISMN isosorbide-5-mononitrate extended release tablets, BP 60 mg THERAPEUTIC CLASSIFICATION Antianginal agent ACTIONS AND CLINICAL PHARMACOLOGY As with other organic nitrates, the principal pharmacological action of isosorbide-5-mononitrate, the major active metabolite of isosorbide dinitrate (ISDN), is relaxation of vascular smooth muscle and consequent dilation of peripheral arteries and veins, especially the latter. Dilation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (pre- load). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (after-load). Dilation of the coronary arteries also occurs. The hemodynamic responses to isosorbide-5-mononitrate are similar to those produced by other nitrates. PHARMACODYNAMICS Dosage regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration. This strategy is inappropriate for organic nitrates. Prolonged administration of nitrate drugs according to traditionally recommended dosage regimens has been shown to produce tolerance. Tolerance results in a loss of efficacy. Several well-controlled clinical trials have used exercise testing to assess the antianginal efficacy of continuously delivered nitrates. In the large majority of these trials, nitrate effectiveness was indistinguishable from placebo after 24 hours (or less) of continuous therapy. Attempts to overcome tolerance by dose escalation, even to doses far in excess of those used acu read_full_document